Amylyx Pharmaceuticals Inc
AMLX8.020USD
+0.305+3.95%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
714.43MCap. mercado
PérdidaP/E TTM
Más Datos de Amylyx Pharmaceuticals Inc Compañía
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.
Información de la empresa
Símbolo de cotizaciónAMLX
Nombre de la empresaAmylyx Pharmaceuticals Inc
Fecha de salida a bolsaJan 07, 2022
Director ejecutivoMr. Justin Klee
Número de empleados123
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 07
Dirección43 Thorndike Street
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02141
Teléfono16176820917
Sitio Webhttps://www.amylyx.com/
Símbolo de cotizaciónAMLX
Fecha de salida a bolsaJan 07, 2022
Director ejecutivoMr. Justin Klee
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Chief Medical Officer
Chief Medical Officer
194.38K
+40.46%
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Dr. George Mclean Milne, Ph.D.
Dr. George Mclean Milne, Ph.D.
Chair of the Board of Directors
Chair of the Board of Directors
--
--
Ms. Lindsey Allen
Ms. Lindsey Allen
IR Contact Officer
IR Contact Officer
--
--
Mr. Joshua B. Cohen
Mr. Joshua B. Cohen
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mr. Paul Fonteyne
Mr. Paul Fonteyne
Independent Director
Independent Director
--
--
Mr. James M. Frates
Mr. James M. Frates
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Karen M. Firestone
Ms. Karen M. Firestone
Independent Director
Independent Director
--
--
Ms. Daphne E. Quimi, CPA
Ms. Daphne E. Quimi, CPA
Independent Director
Independent Director
--
--
Mr. Justin Klee
Mr. Justin Klee
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Camille L. Bedrosian, M.D.
Dr. Camille L. Bedrosian, M.D.
Chief Medical Officer
Chief Medical Officer
194.38K
+40.46%
Dr. Bernhardt (Bernie) Zeiher, M.D.
Dr. Bernhardt (Bernie) Zeiher, M.D.
Independent Director
Independent Director
--
--
Dr. George Mclean Milne, Ph.D.
Dr. George Mclean Milne, Ph.D.
Chair of the Board of Directors
Chair of the Board of Directors
--
--
Ms. Lindsey Allen
Ms. Lindsey Allen
IR Contact Officer
IR Contact Officer
--
--
Mr. Joshua B. Cohen
Mr. Joshua B. Cohen
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mr. Paul Fonteyne
Mr. Paul Fonteyne
Independent Director
Independent Director
--
--
Desglose de ingresos
FY2024
FY2023
FY2022
FY2021
FY2020
FY2019
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
87.37M
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: vie., 25 de jul
Actualizado: vie., 25 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Perceptive Advisors LLC
8.83%
TCG Crossover Management, LLC
6.67%
Adage Capital Management, L.P.
6.39%
The Vanguard Group, Inc.
5.05%
Klee (Justin B)
3.76%
Other
69.30%
Accionistas
Accionistas
Proporción
Perceptive Advisors LLC
8.83%
TCG Crossover Management, LLC
6.67%
Adage Capital Management, L.P.
6.39%
The Vanguard Group, Inc.
5.05%
Klee (Justin B)
3.76%
Other
69.30%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
37.33%
Investment Advisor
25.77%
Individual Investor
9.53%
Private Equity
9.22%
Investment Advisor/Hedge Fund
6.10%
Research Firm
3.54%
Venture Capital
2.72%
Pension Fund
0.22%
Sovereign Wealth Fund
0.13%
Other
5.44%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
402
86.90M
97.48%
-7.80M
2025Q1
421
95.29M
107.20%
-3.35M
2024Q4
427
70.75M
84.73%
-29.75M
2024Q3
419
63.91M
89.33%
-37.09M
2024Q2
415
63.87M
89.96%
-35.05M
2024Q1
393
69.90M
101.03%
-23.62M
2023Q4
373
76.45M
112.48%
-12.85M
2023Q3
341
74.63M
110.02%
-3.94M
2023Q2
310
76.31M
113.70%
-2.01M
2023Q1
276
73.14M
110.85%
-1.57M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Perceptive Advisors LLC
7.87M
8.83%
+1.10M
+16.24%
Mar 31, 2025
TCG Crossover Management, LLC
5.94M
6.67%
+1.30M
+27.99%
Mar 31, 2025
Adage Capital Management, L.P.
5.70M
6.39%
+5.70M
--
Mar 31, 2025
The Vanguard Group, Inc.
4.12M
4.62%
+1.42M
+52.89%
Mar 31, 2025
Klee (Justin B)
3.36M
3.76%
+235.72K
+7.56%
Apr 11, 2025
Cohen (Joshua Barry)
3.36M
3.76%
+299.42K
+9.80%
Apr 11, 2025
Millennium Management LLC
3.08M
3.46%
+2.49M
+418.62%
Mar 31, 2025
Nantahala Capital Management, LLC
2.93M
3.29%
+1.48M
+102.07%
Mar 31, 2025
Citadel Advisors LLC
2.76M
3.09%
+787.07K
+39.94%
Mar 31, 2025
Saturn V Capital Management LP
2.43M
2.72%
+1.54M
+172.92%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Neuroscience and Healthcare ETF
1.03%
Invesco Dorsey Wright SmallCap Momentum ETF
0.44%
Federated Hermes MDT Small Cap Core ETF
0.22%
iShares Micro-Cap ETF
0.1%
Invesco Nasdaq Biotechnology ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.06%
Avantis US Small Cap Equity ETF
0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.04%
iShares Biotechnology ETF
0.04%
Ver más
iShares Neuroscience and Healthcare ETF
Proporción1.03%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporción0.44%
Federated Hermes MDT Small Cap Core ETF
Proporción0.22%
iShares Micro-Cap ETF
Proporción0.1%
Invesco Nasdaq Biotechnology ETF
Proporción0.06%
ProShares Ultra Nasdaq Biotechnology
Proporción0.06%
Avantis US Small Cap Equity ETF
Proporción0.05%
Invesco Russell 2000 Dynamic Multifactor ETF
Proporción0.04%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proporción0.04%
iShares Biotechnology ETF
Proporción0.04%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
